In the News Stocks: Monmouth Real Estate Investment (NYSE:MNR), Midstates Petroleum Company (NYSE:MPO), Apple (NASDAQ:AAPL), KeyCorp. (NYSE:KEY), Sangamo Biosciences (NASDAQ:SGMO)

Monmouth Real Estate Investment Corp. (NYSE:MNR) shares decreased -0.54% in last trading session and ended the day at $9.25. MNR Gross Margin is 83.10% and its has a return on assets of 1.40%. Monmouth Real Estate Investment Corp. (NYSE:MNR) quarterly performance is -3.55%.

Monmouth Real Estate Investment Corporation (MREIC) is a real estate investment trust (REIT). The Company’s investment focus is to own well-located, net leased industrial properties, which are leased to investment-grade tenants on long-term leases. It also holds a portfolio of REIT securities.

Monmouth Real Estate Investment Corp. (NYSE:MNR) announced that it has entered into an agreement to replace its existing $60 million unsecured revolving credit facility, which was set to mature in June 2016 with a new unsecured revolving credit facility (the “Facility”). The Facility is syndicated with three banks led by BMO Capital Markets (“BMO”), as sole lead arranger, sole book runner, and Bank of Montreal as administrative agent, and includes JPMorgan Chase Bank, N.A. (“J.P. Morgan”) and RBC Capital Markets (“RBC”) as co-syndication agents.

Midstates Petroleum Company, Inc. (NYSE:MPO) ended the last trading day at $4.81. Company weekly volatility is calculated as 67.53% and price to cash ratio as 0.23. Midstates Petroleum Company, Inc. (NYSE:MPO) showed a weekly performance of 131.25%.

Midstates Petroleum Company, Inc. is an independent exploration and production company. The Company is engaged in the exploration, development and production of oil, natural gas liquids and natural gas. Its operations are primarily focused on exploration and production activities in the Mississippian Lime, Anadarko Basin and Gulf Coast.

Analysts at Zacks have given a short term rating of hold on Midstates Petroleum Company, Inc. (NYSE:MPO) with a rank of 3. The company has received an average rating of 2.8 from 10 brokerage firms.

Apple Inc. (NASDAQ:AAPL) caters to the Consumer Goods space. It has a net profit margin of 22.60% and weekly performance is -2.26%. On the last day of trading company shares ended up $110.37. Apple Inc. (NASDAQ:AAPL) distance from 50-day simple moving average (SMA50) is -7.63%.

Apple Inc. (Apple) designs, manufactures and markets mobile communication and media devices, personal computers, and portable digital music players, and a variety of related software, services, peripherals, networking solutions, and third-party digital content and applications.

Apple announced a new partnership last week with PayAny where for a new device that helps merchants accept Apple Pay transactions.
It looks to be a nice product that will help Apple Pay make inroads with smaller businesses. It will be available starting this month for $39 exclusively at Apple Stores—quite a coup for a payments company with 400 employees.

KeyCorp. (NYSE:KEY) shares increased 0.98% in last trading session and ended the day at $13.45. Its has a return on assets of 1.00%. KeyCorp. (NYSE:KEY) quarterly performance is -10.44%.

KeyCorp is a bank holding company. The Bank operates through its subsidiary, KeyBank National Association, which is engaged in providing banking services. Through KeyBank and other subsidiaries, the Bank provides a range of retail and commercial banking, commercial leasing, investment management, consumer finance, commercial mortgage servicing and special servicing, and investment banking products and services.

KeyCorp (NYSE: KEY) announced that Don Kimble, Chief Financial Officer, andChris Gorman, President of Key Corporate Bank, will present at the Barclays Global Financial Services Conference in New York Cityon Friday, September 18, 2015, at 9:00 a.m. ET.

Sangamo Biosciences Inc. (NASDAQ:SGMO) caters to the Healthcare space. It has a net profit margin of -59.30% and weekly performance is -14.45%. On the last day of trading company shares ended up $6.63. Sangamo Biosciences Inc. (NASDAQ:SGMO) distance from 50-day simple moving average (SMA50) is -26.36%.

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics.

Sangamo Biosciences (NASDAQ: SGMO), said that it’s restructured a wide-ranging alliance with Dublin-based Shire (NASDAQ: SHPG). Specifically, Shire has returned rights to Sangamo’s experimental programs for hemophilia A and B to the California company, and kept ahold of a prospective treatment for Huntington’s disease and another unspecified program. All rights to other targets that were part of the original deal in 2012 have also been handed back to Sangamo, the two companies said.